The Association of the British Pharmaceutical Industry has commissioned a strategic review of its activities, to be completed by April, in order to define the most appropriate focus and strategy for it, and the structure required to meet industry demands over the next five to 10 years.
The study, by Touche Ross, will take account of the changes which are now underway throughout the entire industry. It will include the participation of all member companies in defining future needs, and will also seek the views of other key ABPI audiences.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze